Clinical trials located in

Salford

Salford city is located in United Kingdom. Currently, 18 clinical trials are being conducted in this city.

Salford, located in Greater Manchester, England, is a city with a rich industrial heritage, notably in textiles and engineering. It became a municipal borough in 1844 and achieved city status in 1926. Salford is home to the University of Salford, established in 1967, contributing significantly to the local economy and culture. The city also boasts the Salford Quays, a regenerated area that houses the BBC and ITV at MediaCityUK, making it a crucial hub for the UK’s media industry. Additionally, Salford has a vibrant arts scene, exemplified by the Lowry, a theater and gallery complex named after the painter L.S. Lowry, known for his scenes of industrial Salford and Manchester.

  • CT-EU-00112545

    Evaluating the Safety and Effectiveness of DYNE-101 for Myotonic Dystrophy Type 1 Patients

    This clinical trial is focused on evaluating a new treatment called DYNE-101 for individuals with Myotonic Dystrophy Type 1 (DM1). The main goal is to see how safe and tolerable this treatment is when given through an intravenous (IV) infusion, which means directly into the vein. The study is designed to carefully monitor how participants respond to multiple doses of DYNE-101 over time.

    The trial is structured into four main phases. It starts with a Screening Period that lasts up to 8 weeks to determine eligibility. Following this, there is a multiple-ascending dose (MAD) Placebo-Controlled Period that goes on for 24 weeks, where the safety and effectiveness of different doses of DYNE-101 are compared against a placebo (a treatment with no active drug). This is to ensure that any changes in participants’ health can be accurately attributed to the treatment. After this phase, there is a Treatment Period of another 24 weeks, where all participants receive DYNE-101. The study concludes with a Long-Term Extension (LTE) Period lasting 96 weeks, aimed at understanding the long-term impacts of the treatment.

    One of the key aspects being monitored throughout the study, up to Week 145, is the number of participants who experience any treatment-emergent adverse events (TEAEs), which are any new or worsening health issues that occur during the trial.

    This study represents an important step towards finding a new treatment option for those living with Myotonic Dystrophy Type 1, with a strong focus on safety and the overall well-being of the participants.

    FranceGermanyItalyNetherlandsUnited Kingdom
  • SPI-62 as new drug for patients with ACTH-dependent Cushing’s syndrome

    This is a study focused on a new treatment option, SPI-62, for people struggling with ACTH-independent Cushing’s Syndrome. The main aim is to evaluate the efficacy and safety of SPI-62 in treating the condition.

    SPI-62 is a drug that works by inhibiting a specific enzyme in the body, potentially reducing excessive cortisol levels that contribute to the disease. During this study, participants will receive SPI-62 in oral tablet form. Dosing will vary, starting at a lower dose and potentially increasing depending on patient response and study requirements.

    The study has been designed as a Phase 2 trial, meaning that the primary focus is on understanding how well SPI-62 can treat the symptoms of hypercortisolism and what its safety profile is. Participants will be in the study for an extended period of time, with scheduled visits at baseline and then at 1, 3, 6, 9 and 12 months, followed by quarterly visits. These visits are crucial to monitor health status and treatment impact.

    One of the key aspects the researchers will be looking at is the change in HbA1c levels, a marker of blood sugar control, after both 6 and 12 weeks of treatment. This will help to understand whether SPI-62 can improve diabetes or the impaired glucose tolerance that often accompanies diabetes.

    FranceRomaniaUnited Kingdom
  • Investigating efficacy and safety of new therapy in early-stage Parkinson’s disease

    This clinical trial aims to examine BIIB122, a new medication considered to potentially slow down the progression of early-stage Parkinson’s disease in patients aged between 30–80 years old. Participants will undergo treatment with either BIIB122 or a placebo equal in appearance but devoid of actual medicine. The trial’s routine includes a single daily medication intake for a timeframe between 48 and 144 weeks. To evaluate the medication’s efficacy, patients’ symptoms and their impact on everyday life will be observed using the Movement Disorder Society-Unified Parkinson’s Disease Rating Scale (MDS-UPDRS). In addition to this, safety assessment of BIIB122 will be a main focus of the study. The trial treats this as a double-blind study, anonymizing whether a patient takes the BIIB122 drug or a placebo.

    AustriaFranceGermanyItalyNetherlandsPolandSpainUnited Kingdom
  • Testing new medicine for resistant high blood pressure

    In this 20-week trial, the effectiveness, safety, and optimal dosage of a medication known as XXB750 are being evaluated in individuals with resistant high blood pressure (resistant hypertension). This condition persists despite the use of three different blood pressure medications. XXB750 will be administered through subcutaneous injections, and its efficacy will be compared to a placebo. A 2-week preparation period precedes the trial, during which participants receive three doses of the actual trial medicine and one dose as part of the preparation. Following the trial, participants will be monitored for an additional 8 weeks without receiving any trial medicine during this period. The primary focus is on assessing whether XXB750 can effectively reduce blood pressure when measured over a 24-hour period.

    AustriaBulgariaCzechiaFranceGermanyItalyNetherlandsPolandSlovakiaSpainUnited Kingdom
  • CT-EU-00041922

    Testing new medication for adult muscle inflammation treatment

    This study aims to test a medicine called Efgartigimod (EFG PH20 SC) for adults who are suffering from a disease called Idiopathic Inflammatory Myopathy (IIM), where muscles become inflamed for unknown reasons. This condition often falls into groups like dermatomyositis, immune-mediated necrotizing myopathy, or specific types of polymyositis. The trial wants to compare how good the medicine is against a placebo. The researchers will look at how much people’s symptoms improve and whether there are any side effects. The test is going to be carried out in many locations and will involve people over 18 years old.

    AustriaBelgiumBulgariaDenmarkFranceGermanyGreeceHungaryItalyNetherlandsPolandPortugalSpainSwedenUnited Kingdom
  • Study on the impact of Retatrutide for overweight patients with kidney disease

    This study is exploring a new treatment for individuals who are overweight or have obesity and suffer from chronic kidney disease, with or without Type 2 Diabetes. It tests a medication called Retatrutide (LY3437943), aiming to improve kidney function. Participants will either receive LY3437943 or a placebo in a controlled and monitored environment. The study spans approximately 31 weeks, involving regular health check-ups and tests to monitor the medication’s effects on kidney function. The goal is to find an effective treatment that can enhance kidney health in patients with these conditions. The study is particularly important for advancing understanding and treatment options for those struggling with kidney issues related to weight and diabetes.

    ItalySpainUnited Kingdom
  • Comparison of different treatments for follicular lymphoma

    This study involves comparing two treatments for a condition known as follicular or marginal zone lymphoma, both of which are types of cancer affecting lymph cells. The first treatment combines zanubrutinib with an antibody called Anti-CD20, while the second treatment involves lenalidomide and rituximab. These treatments are intended for patients who have not responded or have stopped responding to conventional treatment. One of the primary objectives of the study is to determine which treatment is more effective in preventing the cancer from progressing, referred to as progression-free survival. Additionally, the study aims to assess the impact of these treatments on the patients’ quality of life, evaluating various aspects through questionnaires related to physical and emotional well-being, symptoms, and the ability to perform normal activities.

    AustriaCzechiaFranceItalyRomaniaSpainUnited Kingdom
  • Study on dazostinag & pembrolizumab for advanced solid tumors

    The purpose of this study is to test a new drug called dazostinag. A study is being conducted to see whether this drug is helpful in adults with advanced forms of solid cancer. Some people are given dazostinag alone, while others are given it with another medicine called pembrolizumab. Scientists’ focus here is on finding out whether these drugs cause any side effects, and finding out what the maximum dose is that people can take without serious side effects. The study consists of two parts, including a dose escalation phase and a dose escalation phase. In the first part, the dose of dazostinag will be gradually increased, given alone or in combination with pembrolizumab. In the second part, Dazostinag will be tested with pembrolizumab and other anticancer drugs. This section will focus on patients with specific cancers that are difficult to remove or have spread to other parts of the body.

    AustriaBelgiumFrancePolandUnited Kingdom
  • Study on Tolebrutinib’s ability to delay disability progression in multiple sclerosis

    This is a study that involves a specific type of multiple sclerosis (MS) called primary progressive multiple sclerosis (PPMS). In this study, a drug called SAR442168, also known as Tolebrutinib, will be tested against a placebo. The main purpose of the study is to see if this drug can slow down the progression of disability in PPMS. The researchers will also look at the drug’s effect on clinical markers, brain images (MRI), thinking abilities, physical function, and quality of life. They will also consider the safety and tolerability of this drug. How long each person will take the drug can vary, but it will be somewhere between 12 and 60 months.

    AustriaBelgiumBulgariaCzechiaDenmarkFranceGermanyGreeceHungaryItalyNetherlandsNorwayPolandPortugalRomaniaSpainSwedenUnited Kingdom
  • Inhaler treatment study for Mycobacterium Avium complex lung infection

    This study is for adults with lung infections caused by Mycobacterium avium complex. It tests a new inhalation treatment, ALIS (amikacin liposome inhalation suspension), in combination with standard drugs, azithromycin and ethambutol. The aim is to see if ALIS improves respiratory symptoms better than the standard treatment alone. Participants will receive either ALIS or a placebo, along with the standard drugs. The study focuses on safety, symptom improvement, and overall health impact. This research is important for finding more effective treatments for these challenging lung infections.

    AustriaBelgiumDenmarkFranceGermanyGreeceHungaryItalyPolandPortugalSpainUnited Kingdom
  • Continuation of sodium zirconium cyclosilicate (SZC) therapy in patients with kidney diseases after hospitalization

    This clinical trial investigates the use of sodium zirconium cyclosilicate (SZC) in patients with chronic kidney disease (CKD) treated for hyperkalaemia (high potassium levels) in the hospital. The study compares continuing SZC treatment after discharge with standard care to see if SZC is better at maintaining normal potassium levels and reducing hospital visits. It’s open to adults with CKD and hyperkalaemia. The trial aims to improve post-discharge care and reduce health resource use in these patients.

    BelgiumFranceItalyNetherlandsSpainUnited Kingdom
  • Research study on COPD treatment with new drug mitiperstat

    This study is testing a new drug, mitiperstat, for people with moderate to severe chronic obstructive pulmonary disease (COPD). It’s a Phase IIa trial where 288 adults will either get mitiperstat or a placebo. This setup allows researchers to compare the effects of mitiperstat against no treatment to determine if it effectively reduces the severity and frequency of COPD symptoms. The aim is to see if mitiperstat can help reduce COPD symptoms and how safe it is. Participants will take the drug or placebo once a day.

    BulgariaDenmarkGermanyItalyNetherlandsPolandSpainUnited Kingdom
  • Exploring the efficacy and safety of new drug in Psoriasis Treatment

    This clinical trial is for patients suffering from a skin condition called mild to moderate psoriasis. The aim of the study is to check the effectiveness and safety of a new drug called HRO350. HRO350 is a soft capsule containing oil extracted from herring roe (fish roe). This oil contains natural substances called phospholipids, which are rich in certain fatty acids. These substances have the potential to slow or stop the inflammation that causes psoriasis. Patients in the study will take HRO350 capsules or a placebo (a dummy medicine that contains no active substance) every day for up to a year. They will also have an 8-week follow-up period after completing treatment. Approximately 519 patients will participate in the study. The test will involve regular check-ups, including blood and urine tests, and an assessment of the severity of patients’ psoriasis.

    FinlandGermanyNorwayPolandUnited Kingdom
  • Vaccine study for early Parkinson’s disease patients

    This trial tests a new vaccine, ACI-7104.056, in people with early-stage Parkinson’s Disease (PD). It’s a detailed study involving 150 participants, aged 40-75, conducted across multiple centers. The study compares the effects of different doses of the vaccine and a placebo over a period of 100 weeks. Researchers will monitor the vaccine’s safety, its ability to generate an immune response, and its overall impact on Parkinson’s symptoms. The goal is to see if this vaccine can be a promising treatment for those in the early stages of Parkinson’s.

    GermanySpainUnited Kingdom
  • Tackling Niemann-Pick Disease with trappsol cyclo therapy

    Niemann-Pick Disease Type C1 (NPC1) is a rare, genetic disorder characterized by the accumulation of cholesterol and other fats in the body’s cells, affecting the liver, spleen, and brain, leading to neurological and physical difficulties. The study evaluates the drug Trappsol Cyclo, administered every two weeks, to determine if it can safely help manage symptoms and slow disease progression in individuals with NPC1. The research spans 96 weeks, with a focus on children and adults over the age of three and includes a specific study for infants up to age three, emphasizing the careful monitoring of safety and effectiveness.

    GermanyItalyPolandSpainUnited Kingdom
  • Understanding ocrelizumab treatment for progressive multiple sclerosis

    This study is exploring how well ocrelizumab works and its safety for people with progressive multiple sclerosis (MS). MS patients will either receive ocrelizumab or a placebo every 24 weeks to see if it helps with their disability, particularly in the upper limbs. The study will also monitor any side effects. It includes several phases, from initial screening to treatment and follow-ups, ending with a B-cell monitoring phase. The study, started in August 2019, is set to complete by November 2030 and includes 1000 participants who are receiving careful medical oversight.

    BelgiumBulgariaFranceItalyPolandPortugalRomaniaSpainUnited Kingdom
  • Study of new drugs in acute lymphoblastic leukemia

    This clinical trial focuses on improving treatment strategies for acute lymphoblastic leukemia (ALL) in a diverse age group, from infants to young adults up to 45 years old. The study combines standard treatments with new drugs, for example, Inotuzumab Ozogamicin and Blinatumomab. The trial aims to tailor treatment to individual patient needs and reduce toxicity while maintaining treatment quality. By carefully monitoring event- and disease-free survival rates, as well as minimal residual disease responses, the trial aims to improve the standard of care for ALL and improve both survival outcomes and patient quality of life.

    BelgiumDenmarkFinlandFranceGermanyNetherlandsNorwayPortugalSwedenUnited Kingdom
  • Exploring sacituzumab govitecan for HER2-negative breast cancer care

    This study is evaluating a new treatment for patients with a certain type of breast cancer (HER2-negative) who have not had a complete response to initial chemotherapy. Participants are randomly assigned to receive the investigational drug sacituzumab govitecan or a treatment of their physician’s choice, which may be another type of chemotherapy with capecitabinalub, carboplatin or cisplatin. The study is designed to compare the effectiveness of these approaches in preventing cancer recurrence. Patients may also receive hormone therapy if needed. Patients’ safety and response to treatment are being closely monitored throughout the study.

    AustriaBelgiumFranceGermanyItalySpain

See more clinical trials in other cities in United Kingdom:

.